Treats hypertension. ANDA 217396, held by MSN Laboratories. Losartan Potassium.
As of Nov 21, 2026, ANDA 217396 (Losartan Potassium), held by MSN Laboratories, was first approved by FDA on Aug 14, 2023, with 1 approved supplement and 0 published complete response letters.
Losartan potassium tablet is an angiotensin II receptor blocker (ARB) indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 14, 2023 | Original application | Approved | None posted |
| Losartan Potassium25MG · tablet;oral | Losartan Potassium | Rx |
| Losartan Potassium50MG · tablet;oral | Losartan Potassium | Rx |
| Losartan Potassium100MG · tablet;oral | Losartan Potassium | Rx |
| Sep 9, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 14, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters